Hopefully soon they will announce the financial details of the MSA
Novogen has signed a Master Services Agreement (MSA) with Chiltern Oncology in relation to conduct of the phase II clinical trial of GDC-0084.
Chiltern Oncology is a leading international contract research organization, with a specialist capability in trials of novel anti-cancer agents.
The MSA details key terms of the proposed working relationship, but implementation of the study will be subject to further contractual negotiations.
Ann: GDC 0084 progress update, page-4
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)